Alimera faces NICE set back with Iluvien
09:20 EDT 8 Aug 2012 | SCRIP
NICE, the health technology appraisal body for England and Wales, has issued draft guidance declining to recommend Alimera's Iluvien (fluocinolone acetonide) for treating chronic diabetic macular oedema (DMO). The manufacturer's economic modelling.....
Original Article: Alimera faces NICE set back with Iluvien
More From BioPortfolio on "Alimera faces NICE set back with Iluvien"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
